A lthough antimicrobial agents are not indicated for uncomplicated Salmonella infections, fl uoroquinolones and extended-spectrum cephalosporins are potentially lifesaving treatments for extraintestinal infections (1) . The National Antimicrobial Resistance Monitoring System (NARMS) has monitored antimicrobial drug resistance among enteric pathogens since 1996. NARMS has documented decreased susceptibility to each of these drug classes, in most instances among separate serotypes (2) . Historically, decreased susceptibility to fl uoroquinolones, which can be monitored by tracking resistance to nalidixic acid, has been noted among Salmonella serotypes (ser.) Typhi, Senftenberg, and Virchow (2, 3) . More recently, decreased susceptibility to fl uoroquinolones has been noted among Salmonella ser. Enteritidis (4) . Decreased fl uoroquinolone susceptibility has also been seen among nalidixic acid-susceptible isolates (5) . Extended-spectrum cephalosporin resistance was noted among 15 non-Typhi Salmonella NARMS isolates (including 12 ser. Typhimurium) during 1996-1998 (6) . In all instances, extended-spectrum cephalosporin resistance was the result of bla CMY-2 , a class C plasmid-encoded ampC gene (7) . In addition to conferring resistance or decreased susceptibility to extended-spectrum cephalosporins such as ceftiofur and ceftriaxone, this gene also confers resistance to ampicillin (AMP), amoxillin-clavulanate, cephalothin, and cefoxitin. This AmpC resistance phenotype has been seen in strains of Salmonella ser. Newport along with resistance to other drugs including chloramphenicol, streptomycin, sulfamethoxazole, and tetracycline. This MDRAmpC strain rose from 1% (1/77) of Salmonella ser. Newport submissions in 1998 to 25% (31/124) in 2001 (4) . CMY β-lactamases are largely re-sponsible for extended-spectrum cephalosporin resistance among Salmonella ser. Newport, Typhimurium, and others isolated in North America (6, 8) .
Coresistance to fl uoroquinolones and extended-spectrum cephalosporins would limit therapeutic options for Salmonella infections. Decreased susceptibility to both drug classes was identifi ed in Thailand in 1993 (ser. Anatum, Derby, Enteritidis, Typhimurium, Weltevreden, and I 4,5,12:i:-) (9), the United Kingdom in 1998 (ser. Senftenberg, Typhimurium, and Virchow) (10) (14) . In the United States, 27 (4.6%) of 588 Salmonella ser. Typhimurium isolates (clinical and slaughter) obtained from food animals in 1999 were resistant to ceftiofur and nalidixic acid: 22 (81%) from turkeys, 4 (15%) from horses, and 1 (4%) from cattle (15) .
To understand coresistance to both antimicrobial classes among Salmonella isolates obtained from humans in the United States, we studied the NARMS human collection from 1996 through 2004, looking for decreased susceptibility to quinolones and extended-spectrum cephalosporins. Information for some of the isolates has been presented elsewhere (3, 13, (16) (17) (18) . We present the molecular epidemiology of this phenotype and mechanisms responsible for its decreased susceptibility.
Materials and Methods
Isolates and Antimicrobial Drug Susceptibility Testing NARMS-participating state and local public health laboratories submitted non-Typhi Salmonella isolates to the Centers for Disease Control and Prevention (CDC) for antimicrobial susceptibility testing: every 10th isolate from 1996 through 2002 and every 20th isolate from 2003 to present. Serotypes were determined by the submitting laboratory and, for this study, were confi rmed by the CDC National Salmonella Reference Laboratory according to the KaufmannWhite scheme as described (19) . MICs were determined by using broth microdilution (Sensititre, Westlake, OH, USA). Isolates exhibiting an amikacin MIC >4 μg/mL were confi rmed by Etest (ABBiodisk, Piscataway, NJ, USA). Criteria for decreased susceptibility to quinolones and extendedspectrum cephalosporins were as follows: MIC >32 μg/mL for nalidixic acid or >0.12 μg/mL for ciprofl oxacin and >2 μg/mL for ceftiofur or ceftriaxone. Susceptibility testing was performed according to manufacturer's instructions by using control strains Escherichia coli ATCC25922 and ATCC35218, and Klebsiella pneumoniae ATCC700603 (for extended-spectrum β-lactamase [ESBL] confi rmation only). When available, Clinical Laboratory Standards Institute (CLSI) guidelines were used for interpretation (20) .
Isoelectric Focusing for β-Lactamases
The methods of Rasheed et al. were used with modifi cation (21) . Three-hour trypticase soy broth cultures (grown at 37°C with shaking at 300 rpm) were pelleted, resuspended in 0.2% sodium acetate to 5% of original culture volume, and freeze-thawed 4 times (dry ice/ethanol bath and 37°C water bath). Preparations were diluted 2-fold with distilled water and swirled occasionally on ice for 30 min. Supernatants were collected after centrifugation (30 min at 20,200× g), and 3-5-μL aliquots were resolved for 1.5 h on Ampholine PAGplate polyacrylamide gels, pH 3.5-9.5 (APBiotech, Piscataway, NJ, USA). Gels were stained with nitrocefi n (500 μg/mL; Becton Dickinson, Franklin Lakes, NJ, USA). Isoelectric points (pIs) were estimated by comparison with the following standard β-lactamases: TEM-12 (pI 5.25), KPC-2 (pI 6.7), SHV-3 (pI 7.0), SHV-18 (pI 7.8), and MIR-1 (pI 8.4).
PCR Detection of Antimicrobial Drug Resistance Genes
Presence of qnr genes was determined by using PCR with primers QP1 and QP2 for qnrA (22) , FQ1 and FQ2 for qnrB (23) , and 5′-ATGGAAACCTACAAT-CATAC-3′ and 5′-AAAAACACCTCGACTTAAGT-3′ for qnrS. The qnrB allele was determined by amplifi cation and sequencing with primers FQ1 and FQ2. Screening for aac(6′)-Ib-cr was performed as described (24) . Primer pairs used for amplifi cation of β-lactamase genes were: bla CMY (5′-ATGATGAAAAAATCGTTATGC-3′) and (5′-TTGCAGCTTTTCAAGAATGCGC-3′) (25) ; bla OXA-1 (5′-AATGGCACCAGATTCAACTT-3′) and 5′-CTTGGCTTTTATGCTTGATG-3′) (26) ; bla TEM (5′-TTC TTGAAGACGAAAGGGC-3′) and (5′-ACGCTCAGTG GAACGAAAAC-3′) (27) ; and bla SHV (5′-GGTTATGCGT TATATTCGCC-3′) and (5′-TTAGCGTTGCCAGTGCTC-3′) (28) or at Lahey (5′-GCCGGGTTATTCTTATTTGTC-3′) and (5′-TCTTTCCGATGCCGCCGCCAG-3′) (29) . bla CTX-M genes were screened by using a multiplex PCR assay (30) .
DNA Sequencing
Full-length sequences were obtained for β-lactamase genes. A 255-bp region covering the quinolone-resistant determining region (QRDR) of gyrA (Met52 to Leu137) was amplifi ed by using primers gyrA1: 5′-CATGAACG-TATTGGGCAATG-3′ and gyrA2: 5′-AGATCGGCCAT-CAGTTCGTG-3′. QRDRs of gyrB, parC, and parE were amplifi ed and sequenced by using previously described primers (31) , except primers parCF (5′-ATCGTGCGTT GCCGTTTAT-3′) and parCR (5′-GCCGCTTTCGC CACTTC-3′) were used to enhance coverage of parC. Amplicons were sequenced by using ABI Big-Dye 3.1 chemistry and ABI 3730XL automated DNA sequencers (PE Bio-systems, Foster City, CA, USA). Analysis was performed by using BioEdit (www.mbio.ncsu.edu/BioEdit/bioedit. htmL) or SeqMan software (DNAStar, Madison, WI, USA). QRDR sequences of gyrA, gyrB, parC, and parE were compared with those of Salmonella ser. Typhimurium LT2 (GenBank accession nos. AE008801, AE008878, AE008846, and AE008846, respectively).
Pulsed-Field Gel Electrophoresis (PFGE)
PFGE was performed as previously described (32) . Isolates that produced indistinguishable patterns with XbaI (Roche Molecular Biochemicals, Indianapolis, IN, USA) were restricted with BlnI. Patterns were analyzed by using the BioNumerics version 4.0 software (Applied Maths, Sint-Martens-Latem, Belgium) and compared by unweighted pair group method with averages by using the Dice coeffi cient with a 1.5% band position tolerance window. The DNA sequence and deduced amino acid sequence for the Salmonella ser. Senftenberg bla CMY-23 gene were assigned GenBank accession no. DQ463751.
Results
Decreased susceptibility to quinolones and extendedspectrum cephalosporins was fi rst noted in NARMS data in 1997 and represented 0.19% (27/14,043) of non-Typhi Salmonella from 1996 through 2004 (Table 1) . Salmonella ser. Senftenberg was the most frequent serotype (n = 11), followed by Typhimurium (n = 6), Newport (n = 3), and Enteritidis (n = 2). The phenotype was found in 9 different serotypes in 13 states (Table 2) .
PFGE comparison by XbaI and, if applicable, BlnI restriction showed that 15/27 Salmonella isolates differed by >1 band. No indistinguishable patterns among different Salmonella serotypes were identifi ed. Of the 3 ser. Newport isolates tested, 2 (AM15201 and AM21465) had indistinguishable XbaI patterns but different BlnI patterns (87.51% similarity). The 2 Enteritidis isolates (AM09124 and AM15266) were indistinguishable by both enzymes.
Of the 11 ser. Senftenberg isolates, 5 exhibited unique XbaI PFGE patterns, while the remaining 6 were separated into 2 groups with indistinguishable XbaI PFGE patterns (group 1: AM06960, AM08081, AM16094, and AM19422; group 2: AM20227 and AM20256). BlnI restriction demonstrated that AM19422 differed from the other group 1 isolates by a single band difference (97.44% similarity). PFGE results for some of the Senftenberg isolates are described elsewhere (16, 18) . All Typhimurium isolates exhibited unique XbaI PFGE patterns (77%-93% similarity).
Antimicrobial drug susceptibility results are presented in Table 3 . For nalidixic acid, 25 isolates exhibited an MIC >32 μg/mL, and 2 (Mbandaka and Newport) had an MIC of 16 μg/mL. For ciprofl oxacin, MICs of 0.12-0.5 μg/mL were found for all isolates except the 11 Senftenberg, for which the MIC was >4 μg/mL. For ceftiofur, 14 isolates exhibited resistance (MIC >8 μg/mL). For ceftriaxone, 2 isolates exhibited resistance according to the current CLSI breakpoint (64 μg/mL), and 7 exhibited intermediate resistance (MIC 16 or 32 μg/mL). Three isolates (Mbandaka, Senftenberg, and Typhimurium) exhibited an ESBL phenotype according to ceftazidime and cefotaxime MIC alone and with clavulanate. Seven isolates exhibited the MDRAmpC phenotype, including 1 Agona, 2 Newport, 3 Typhimurium, and 1 Uganda. According to current CLSI guidelines, 1 isolate (ser. Senftenberg) was fully resistant to ciprofl oxacin, ceftriaxone, ceftazidime, and cefotaxime.
The mechanisms responsible for resistance and decreased susceptibility are shown in Table 4 . Some mechanisms for some of the isolates are presented elsewhere (3, 17, 18) . At least 1 gyrA mutation was found in 26 of 27 isolates. A gyrA mutation at codon 83 only was found for 11 isolates; a mutation at codon 87 only was found for 3; mutations at both codons were found for 12. No functional mutations were detected in gyrB or parE genes. All Senftenberg isolates had parC mutations (S80I and T57S), and 6 other isolates had the T57S mutation. In addition to the T57S mutation in parC, the Mbandaka isolate contained a *NARMS, National Antimicrobial Resistance Monitoring System. Reduced susceptibility to quinolones and extended-spectrum cephalosporins defined as MIC >32 μg/mL for nalidixic acid or >0.12 μg/mL for ciprofloxacin and >2 μg/mL for ceftiofur or >2 μg/mL for ceftriaxone.
plasmid-mediated qnrB2 gene and has been described (13) . Four isolates contained aac(6′)-Ib, but none contained the ciprofl oxacin-modifying aac(6′)-Ib-cr variant. Nine AmpC phenotype isolates produced β-lactamase with a pI >8.4 (Table 4); 8 contained bla CMY-2 , but the Senftenberg strain contained a bla CMY-23 gene (GenBank accession no. DQ463751) identical to that found in an E. coli isolate (GenBank accession no. DQ438952). This gene differs from bla CMY-2 by 1 amino acid. Three of the bla CMYpositive isolates, including the strain positive for bla , also contained bla TEM-1b . The Mbandaka isolate was positive for bla SHV-30 with pI 7.0 (33) and also produced an enzyme with a pI 7.6, the nature of which is still under study. Two isolates (1 Senftenberg and 1 Typhimurium) contained bla , and both also contained bla OXA and bla TEM-1 genes. Of the 11 Senftenberg isolates, 10 contained bla OXA-1 (n = 9) or bla OXA-9 (n = 1). No isolates contained bla CTX-M genes.
Discussion
Fluoroquinolone and extended-spectrum cephalosporin coresistance is rare; however, the appearance of this phenotype in 2 commonly isolated serotypes from humans (Typhimurium and Newport) is concerning. Sporadic infections are alarming, but if clonal expansion of an isolate with this phenotype were to take place, as occurred with Salmonella ser. Typhimurium DT104 and NewportMDRAmpC, the clinical consequences could be dramatic. Statistically signifi cant increases in resistance to nalidixic acid (odds ratio [OR] 6.7, 95% confi dence interval [CI] CI 2.6-17.7) and ceftiofur (OR 43.2, 95% CI 10.5-177.4) have been documented among non-Typhi Salmonella of human origin submitted to NARMS during 1996-2003 (4). Of 202 nalidixic acid-resistant non-Typhi Salmonella collected by NARMS during 1996-2003, most were ser. Enteritidis (31%) or Typhimurium (10%). Most of the 324 ceftiofur-resistant non-Typhi Salmonella collected by NARMS during the same time period were ser. Newport (56%) or Typhimurium (23%). A slightly broader geographic representation can be found in the SENTRY surveillance project, which analyzed 786 Salmonella isolates (blood and stool) from medical facilities in Latin America and North America (including Canada) during 2001-2003 (8) . Of these, 11% were resistant to nalidixic acid, and 2% exhibited decreased susceptibility to ceftazidime, ceftriaxone, or aztreonam.
Extended-spectrum cephalosporin-resistant Newport and Typhimurium isolates are typically obtained from community-acquired infections. Newport-MDRAmpC infections have been associated with consumption of contaminated beef and unpasteurized dairy products (34) . Salmonella containing bla CMY genes have been isolated from ground chicken (Typhimurium DT208), turkey (Agona), and beef (Agona) purchased from retail outlets in the Washington DC area (35) . In addition, cattle, chickens, turkeys, pigs, horses, and dogs have all been sources of bla CMYcontaining Salmonella, including common serotypes such as Typhimurium, Newport, and Heidelberg (26, 36, 37) . Decreased susceptibility to fl uoroquinolones among Salmonella serotypes that typically carry bla CMY genes warrants exploration of factors that could select for decreased susceptibility to fl uoroquinolones in animal reservoirs and in the human host.
PFGE showed diversity within some serotypes and indistinguishable strains within others. PFGE diversity among 2 serotypes commonly associated with extendedspectrum cephalosporin resistance (Newport and Typhimurium) is not surprising, given that CMY-producing strains have been seen at least since the late 1990s. Isolates of ser. Enteritidis are highly clonal; therefore, PFGE-indistinguishable patterns among isolates with no apparent epidemiologic link are not unusual. All PFGE-indistinguishable Senftenberg isolates from group 1 were isolated in the same state. Results for the Florida Senftenberg isolates are described elsewhere (16, 18) .
Salmonella ser. Senftenberg exhibiting decreased susceptibility to fl uoroquinolones has been associated with (39) ; bla OXA-9 has been associated with Tn1331 (40) . The epidemiology of Salmonella with decreased susceptibility to fl uoroquinolones is relatively well characterized, as is that of Salmonella with bla CMY -mediated extended-spectrum cephalosporin resistance. Conversely, little is known about the events leading to quinolone and extendedspectrum cephalosporin coresistance and the epidemiology of these infections in humans. Patients with Salmonella infections who exhibit decreased susceptibility to both antimicrobial drug classes should be interviewed to determine risk factors and the effects of antimicrobial drugs and other potential selective factors on this phenomenon.
